- Home
- LPCN vs PHIO Comparison
LPCN vs PHIO Comparison
Compare LPCN & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- PHIO
- Stock Information
- Founded
- LPCN 1997
- PHIO 2011
- Country
- LPCN United States
- PHIO United States
- Employees
- LPCN N/A
- PHIO N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- PHIO Health Care
- Exchange
- LPCN Nasdaq
- PHIO Nasdaq
- Market Cap
- LPCN 13.8M
- PHIO 12.8M
- IPO Year
- LPCN N/A
- PHIO N/A
- Fundamental
- Price
- LPCN $3.18
- PHIO $1.18
- Analyst Decision
- LPCN Strong Buy
- PHIO Strong Buy
- Analyst Count
- LPCN 1
- PHIO 3
- Target Price
- LPCN $7.00
- PHIO $10.67
- AVG Volume (30 Days)
- LPCN 54.7K
- PHIO 8.8M
- Earning Date
- LPCN 11-06-2025
- PHIO 11-13-2025
- Dividend Yield
- LPCN N/A
- PHIO N/A
- EPS Growth
- LPCN N/A
- PHIO N/A
- EPS
- LPCN N/A
- PHIO N/A
- Revenue
- LPCN $4,322,693.00
- PHIO N/A
- Revenue This Year
- LPCN N/A
- PHIO N/A
- Revenue Next Year
- LPCN N/A
- PHIO N/A
- P/E Ratio
- LPCN N/A
- PHIO N/A
- Revenue Growth
- LPCN N/A
- PHIO N/A
- 52 Week Low
- LPCN $2.52
- PHIO $0.97
- 52 Week High
- LPCN $5.50
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- LPCN 61.21
- PHIO 24.02
- Support Level
- LPCN $3.07
- PHIO $1.08
- Resistance Level
- LPCN $3.32
- PHIO $1.32
- Average True Range (ATR)
- LPCN 0.20
- PHIO 0.14
- MACD
- LPCN 0.06
- PHIO -0.03
- Stochastic Oscillator
- LPCN 65.82
- PHIO 16.05
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.